Brokerages Set Globus Medical, Inc. (NYSE:GMED) Target Price at $101.77

Globus Medical, Inc. (NYSE:GMED) has been given a consensus rating of “Moderate Buy” by the seventeen brokerages that are presently covering the stock, Marketbeat reports. Five research analysts have rated the stock with a hold rating, nine have issued a buy rating and three have issued a strong buy rating on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $101.7692.

A number of equities research analysts have recently weighed in on GMED shares. Wells Fargo & Company dropped their price objective on Globus Medical from $103.00 to $99.00 and set an “overweight” rating for the company in a research note on Friday, August 7th. BMO Capital Markets initiated coverage on Globus Medical in a report on Wednesday, July 8th. They set an “outperform” rating and a $94.00 target price for the company. Zacks Research raised Globus Medical from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 10th. Piper Sandler cut their price target on shares of Globus Medical from $115.00 to $100.00 and set an “overweight” rating on the stock in a research note on Monday, June 15th. Finally, Royal Bank Of Canada cut their price target on shares of Globus Medical from $120.00 to $115.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th.

Globus Medical Stock Performance

Globus Medical stock opened at $75.03 on Friday. The company’s 50 day simple moving average is $80.67 and its 200-day simple moving average is $84.12. Globus Medical has a 1 year low of $54.15 and a 1 year high of $101.40. The company has a market capitalization of $10.07 billion, a price-to-earnings ratio of 19.19, a price-to-earnings-growth ratio of 1.26 and a beta of 0.95.

Globus Medical (NYSE:GMED) last posted its quarterly earnings data on Thursday, August 6th. The medical device company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.10 by $0.24. The firm had revenue of $789.61 million during the quarter, compared to analysts’ expectations of $782.88 million. Globus Medical had a net margin of 17.02% and a return on equity of 14.57%. The firm’s quarterly revenue was up 5.9% on a year-over-year basis. During the same quarter last year, the company posted $0.86 EPS. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. Equities analysts expect that Globus Medical will post 4.99 earnings per share for the current year.

Insider Buying and Selling at Globus Medical

In related news, Director Stephen Zarrilli sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the sale, the director directly owned 25,000 shares of the company’s stock, valued at $2,176,000. This represents a 50.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 18.38% of the company’s stock.

Hedge Funds Weigh In On Globus Medical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Elevation Wealth Partners LLC increased its position in shares of Globus Medical by 2,178.6% during the second quarter. Elevation Wealth Partners LLC now owns 319 shares of the medical device company’s stock worth $25,000 after acquiring an additional 305 shares during the period. Continuum Advisory LLC purchased a new position in Globus Medical in the second quarter valued at $25,000. Advisory Services Network LLC acquired a new position in Globus Medical during the 3rd quarter worth $26,000. EverSource Wealth Advisors LLC grew its stake in Globus Medical by 74.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after purchasing an additional 197 shares in the last quarter. Finally, SBI Securities Co. Ltd. increased its holdings in Globus Medical by 98.2% during the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after purchasing an additional 167 shares during the period. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.